Cargando…

Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice

Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus, may eventually leads to irreversible heart failure. Metformin is the cornerstone of diabetes therapy, especially for type 2 diabetes. Statins are widely used to reduce the risk of cardiovascular diseases. In this study, we ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Weikun, Bai, Tao, Zeng, Jiang, Niu, Zijing, Fan, Daogui, Xu, Xin, Luo, Meiling, Wang, Peijian, Zou, Qingliang, Dai, Xiaozhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945946/
https://www.ncbi.nlm.nih.gov/pubmed/33718370
http://dx.doi.org/10.3389/fcell.2021.634900
_version_ 1783662961009623040
author Jia, Weikun
Bai, Tao
Zeng, Jiang
Niu, Zijing
Fan, Daogui
Xu, Xin
Luo, Meiling
Wang, Peijian
Zou, Qingliang
Dai, Xiaozhen
author_facet Jia, Weikun
Bai, Tao
Zeng, Jiang
Niu, Zijing
Fan, Daogui
Xu, Xin
Luo, Meiling
Wang, Peijian
Zou, Qingliang
Dai, Xiaozhen
author_sort Jia, Weikun
collection PubMed
description Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus, may eventually leads to irreversible heart failure. Metformin is the cornerstone of diabetes therapy, especially for type 2 diabetes. Statins are widely used to reduce the risk of cardiovascular diseases. In this study, we aimed to investigate whether the combined administration of metformin and atorvastatin could achieve superior protective effects on DCM and to elucidate its molecular mechanism. Here, db/db mice (9–10 weeks old) were randomly divided into four groups, including sterile water group (DM), metformin group (MET, 200 mg/kg/day), atorvastatin group (AVS, 10 mg/kg/day), and combination therapy group (MET + AVS). Mice were treated with different drugs via gavage once per day for 3 months. After 3 months of treatment, the pathological changes (inflammation, fibrosis, hypertrophy, and oxidative stress makers) were detected by histopathological techniques, as well as Western blotting. The H9C2 cardiomyocytes were treated with palmitate (PAL) to mimic diabetic condition. The cells were divided into control group, PAL treatment group, MET + PAL treatment group, AVS + PAL treatment group, and MET + AVS + PAL treatment group. The effects of MET and AVS on the cell viability and inflammation of H9C2 cells subjected to PAL condition were evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, immunofluorescence staining, and Western blotting. Both MET and AVS prevented diabetes-induced fibrosis, hypertrophy, and inflammation. The combination therapy showed superior effects in protecting myocardial tissue against diabetes-induced injury. Mechanistically, the combination therapy significantly inhibited oxidative stress and the expression levels of inflammation-related proteins, e.g., NLRP3, caspase-1, interleukin-1β (IL-1β), Toll-like receptor 4 (TLR4), and P-p65/p65, in both cardiac tissues and H9C2 cells. TUNEL assay showed that the combination therapy significantly attenuated the apoptosis of cardiomyocytes; decreased the expression level of pro-apoptotic-related proteins, such as cleaved caspase-3 and BAX; and enhanced the expression level of anti-apoptotic protein (Bcl-2). Furthermore, the combination therapy remarkably upregulated the expression levels of 5′-AMP-activated protein kinase (AMPK) and SIRT1. Our findings indicated that the anti-inflammation and anti-apoptosis effects of the combination therapy may be related to activation of AMPK/SIRT1 signaling pathway.
format Online
Article
Text
id pubmed-7945946
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79459462021-03-11 Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice Jia, Weikun Bai, Tao Zeng, Jiang Niu, Zijing Fan, Daogui Xu, Xin Luo, Meiling Wang, Peijian Zou, Qingliang Dai, Xiaozhen Front Cell Dev Biol Cell and Developmental Biology Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus, may eventually leads to irreversible heart failure. Metformin is the cornerstone of diabetes therapy, especially for type 2 diabetes. Statins are widely used to reduce the risk of cardiovascular diseases. In this study, we aimed to investigate whether the combined administration of metformin and atorvastatin could achieve superior protective effects on DCM and to elucidate its molecular mechanism. Here, db/db mice (9–10 weeks old) were randomly divided into four groups, including sterile water group (DM), metformin group (MET, 200 mg/kg/day), atorvastatin group (AVS, 10 mg/kg/day), and combination therapy group (MET + AVS). Mice were treated with different drugs via gavage once per day for 3 months. After 3 months of treatment, the pathological changes (inflammation, fibrosis, hypertrophy, and oxidative stress makers) were detected by histopathological techniques, as well as Western blotting. The H9C2 cardiomyocytes were treated with palmitate (PAL) to mimic diabetic condition. The cells were divided into control group, PAL treatment group, MET + PAL treatment group, AVS + PAL treatment group, and MET + AVS + PAL treatment group. The effects of MET and AVS on the cell viability and inflammation of H9C2 cells subjected to PAL condition were evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, immunofluorescence staining, and Western blotting. Both MET and AVS prevented diabetes-induced fibrosis, hypertrophy, and inflammation. The combination therapy showed superior effects in protecting myocardial tissue against diabetes-induced injury. Mechanistically, the combination therapy significantly inhibited oxidative stress and the expression levels of inflammation-related proteins, e.g., NLRP3, caspase-1, interleukin-1β (IL-1β), Toll-like receptor 4 (TLR4), and P-p65/p65, in both cardiac tissues and H9C2 cells. TUNEL assay showed that the combination therapy significantly attenuated the apoptosis of cardiomyocytes; decreased the expression level of pro-apoptotic-related proteins, such as cleaved caspase-3 and BAX; and enhanced the expression level of anti-apoptotic protein (Bcl-2). Furthermore, the combination therapy remarkably upregulated the expression levels of 5′-AMP-activated protein kinase (AMPK) and SIRT1. Our findings indicated that the anti-inflammation and anti-apoptosis effects of the combination therapy may be related to activation of AMPK/SIRT1 signaling pathway. Frontiers Media S.A. 2021-02-16 /pmc/articles/PMC7945946/ /pubmed/33718370 http://dx.doi.org/10.3389/fcell.2021.634900 Text en Copyright © 2021 Jia, Bai, Zeng, Niu, Fan, Xu, Luo, Wang, Zou and Dai. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Jia, Weikun
Bai, Tao
Zeng, Jiang
Niu, Zijing
Fan, Daogui
Xu, Xin
Luo, Meiling
Wang, Peijian
Zou, Qingliang
Dai, Xiaozhen
Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice
title Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice
title_full Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice
title_fullStr Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice
title_full_unstemmed Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice
title_short Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice
title_sort combined administration of metformin and atorvastatin attenuates diabetic cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative stress in type 2 diabetic mice
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945946/
https://www.ncbi.nlm.nih.gov/pubmed/33718370
http://dx.doi.org/10.3389/fcell.2021.634900
work_keys_str_mv AT jiaweikun combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT baitao combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT zengjiang combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT niuzijing combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT fandaogui combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT xuxin combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT luomeiling combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT wangpeijian combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT zouqingliang combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice
AT daixiaozhen combinedadministrationofmetforminandatorvastatinattenuatesdiabeticcardiomyopathybyinhibitinginflammationapoptosisandoxidativestressintype2diabeticmice